The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Open accessAbstract
BACKGROUND: Poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are rare and frequently lethal tumors that so far have not been subjected to comprehensive genetic characterization. METHODS: We performed next-generation sequencing of 341 cancer genes from 117 patient-derived PDTCs and ATCs and analyzed the transcriptome of a representative subset of 37 tumors. Results were analyzed in the context of The Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC). RESULTS: Compared to PDTCs, ATCs had a greater mutation burden, including a higher frequency of mutations in TP53, TERT promoter, PI3K/AKT/mTOR pathway effectors, SWI/SNF subunits, and histone methyltransferases. BRAF and RAS were the predominant drivers and dictated distinct tropism for nodal versus distant metastases in PDTC. RAS and BRAF sharply distinguished between PDTCs defined by the Turin (PDTC-Turin) versus MSKCC (PDTC-MSK) criteria, respectively. Mutations of EIF1AX, a component of the translational preinitiation complex, were markedly enriched in PDTCs and ATCs and had a striking pattern of co-occurrence with RAS mutations. While TERT promoter mutations were rare and subclonal in PTCs, they were clonal and highly prevalent in advanced cancers. Application of the TCGA-derived BRAF-RAS score (a measure of MAPK transcriptional output) revealed a preserved relationship with BRAF/RAS mutation in PDTCs, whereas ATCs were BRAF-like irrespective of driver mutation. CONCLUSIONS: These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance. The widespread genomic disruptions in ATC compared with PDTC underscore their greater virulence and higher mortality. FUNDING: This work was supported in part by NIH grants CA50706, CA72597, P50-CA72012, P30-CA008748, and 5T32-CA160001; the Lefkovsky Family Foundation; the Society of Memorial Sloan Kettering; the Byrne fund; and Cycle for Survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationGene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationA Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
The role of microRNA genes in papillary thyroid carcinoma
He, H., Jazdzewski, K., Li, W., Liyanarachchi, S., Nagy, R., Volinia, S., Calin, G. A., Liu, C.-G., Franssila, K., Suster, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509603102 · Cited by 1,215
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Self-citationMolecular genetics and diagnosis of thyroid cancer
Nikiforov, Y. E., & Nikiforova, M. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.142 · Cited by 1,011
Pathogenetic mechanisms in thyroid follicular-cell neoplasia
Kondo, T., Ezzat, S., & Asa, S. L. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1836 · Cited by 893
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC
Soares, P., Trovisco, V., Rocha, A. S., Lima, J., Castro, P., Preto, A., Máximo, V., Botelho, T., Seruca, R., & Sobrinho-Simões, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206706 · Cited by 679
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., & Koeffler, H. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116168 · Cited by 649
Self-citationVolante, M., Collini, P., Nikiforov, Y. E., Sakamoto, A., Kakudo, K., Katoh, R., Lloyd, R. V., LiVolsi, V. A., Papotti, M., Sobrinho-Simoes, M., et al. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180309e6a · Cited by 619
Pratilas, C. A., Taylor, B. S., Ye, Q., Viale, A., Sander, C., Solit, D. B., & Rosen, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900780106 · Cited by 614
Self-citationHighly prevalent TERT promoter mutations in aggressive thyroid cancers
Liu, X., Bishop, J., Shan, Y., Pai, S., Liu, D., Murugan, A. K., Sun, H., El-Naggar, A. K., & Xing, M. (2013) · Endocrine-Related Cancer · doi:10.1530/erc-13-0210 · Cited by 613
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3734 · Cited by 555
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Ricarte-Filho, J. C., Ryder, M., Chitale, D. A., Rivera, M., Heguy, A., Ladanyi, M., Janakiraman, M., Solit, D., Knauf, J. A., Tuttle, R. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0727 · Cited by 529
Self-citationAnaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies
Smallridge, R. C., & Copland, J. A. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.013 · Cited by 481
Landa, I., Ganly, I., Chan, T. A., Mitsutake, N., Matsuse, M., Ibrahimpasic, T., Ghossein, R. A., & Fagin, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2383 · Cited by 462
Self-citationRyder, M., Ghossein, R. A., Ricarte-Filho, J. C. M., Knauf, J. A., & Fagin, J. A. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0036 · Cited by 443
Self-citationLiu, Z., Hou, P., Ji, M., Guan, H., Studeman, K., Jensen, K., Vasko, V., El-Naggar, A. K., & Xing, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0273 · Cited by 390
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., & Berger, N. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115743 · Cited by 390
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., & Pierotti, M. A. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116385 · Cited by 370
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N., Nelson-Williams, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 364
(1992) · American Journal of Otolaryngology · doi:10.1016/0196-0709(92)90038-u · Cited by 350
Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer
García-Rostán, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. A., Herrero, A., Fusco, A., Cameselle-Teijeiro, J., & Santoro, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4259 · Cited by 338
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Wagle, N., Grabiner, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321
Hiltzik, D., Carlson, D. L., Tuttle, R. M., Chuai, S., Ishill, N., Shaha, A., Shah, J. P., Singh, B., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.21739 · Cited by 312
Self-citationFrequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.
Garcia-Rostan, G., Tallini, G., Herrero, A., D'Aquila, T. G., Carcangiu, M. L., & Rimm, D. L. (1999) · PubMed · Cited by 308
Vulnerabilities of Mutant SWI/SNF Complexes in Cancer
Helming, K. C., Wang, X., & Roberts, C. W. M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.018 · Cited by 303
Frequent mutation and nuclear localization of betacatenin in anaplastic thyroid carcinoma
Gineza, G. (1999) · Cancer Research · Cited by 303
Liu, T., Wang, N., Cao, J., Sofiadis, A., Dinets, A., Zedenius, J., Larsson, C., & Xu, D. (2014) · Oncogene · doi:10.1038/onc.2013.446 · Cited by 251
Nikiforov, Y. E. (2004) · Endocrine Pathology · doi:10.1385/ep:15:4:319 · Cited by 234
Cremona, C. A., & Behrens, A. (2014) · Oncogene · doi:10.1038/onc.2013.275 · Cited by 204
Alekseyenko, A. A., Walsh, E. M., Wang, X., Grayson, A. R., Hsi, P. T., Kharchenko, P. V., Kuroda, M. I., & French, C. A. (2015) · Genes & Development · doi:10.1101/gad.267583.115 · Cited by 198
Caillou, B., Talbot, M., Weyemi, U., Pioche-Durieu, C., Al Ghuzlan, A., Bidart, J. M., Chouaib, S., Schlumberger, M., & Dupuy, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022567 · Cited by 191
BRAF V600E Inhibition in Anaplastic Thyroid Cancer
Rosove, M. H., Peddi, P. F., & Glaspy, J. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215697 · Cited by 179
Genome-Wide Appraisal of Thyroid Cancer Progression
Wreesmann, V. B., Ghossein, R. A., Patel, S. G., Harris, C. P., Schnaser, E. A., Shaha, A. R., Tuttle, R. M., Shah, J. P., Rao, P. H., & Singh, B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64433-1 · Cited by 178
Self-citationAn evidence‐based review of poorly differentiated thyroid cancer
Sanders, E. M., LiVolsi, V. A., Brierley, J., Shin, J., & Randolph, G. W. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9033-3 · Cited by 177
McFadden, D. G., Vernon, A., Santiago, P. M., Martinez-McFaline, R., Bhutkar, A., Crowley, D. M., McMahon, M., Sadow, P. M., & Jacks, T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404357111 · Cited by 166
Coates, P. J., Rundle, J. K., Lorimore, S. A., & Wright, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3050 · Cited by 159
García-Rendueles, M. E. R., Ricarte‐Filho, J. C., Untch, B. R., Landa, I., Knauf, J. A., Voza, F. A., Smith, V. E., Ganly, I., Taylor, B. S., Persaud, Y., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0330 · Cited by 151
Self-citationp53 Gene Mutations Associated with Anaplastic Transformation of Human Thyroid Carcinomas
Nakamura, T., Yana, I., Kobayashi, T., Shin, E., Karakawa, K., Fujita, S., Miya, A., Mori, T., Nishisho, I., & Takai, S. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb02761.x · Cited by 138
N‐ and C‐terminal residues of eIF1A have opposing effects on the fidelity of start codon selection
Fekete, C. A., Mitchell, S. F., Cherkasova, V., Applefield, D., Algire, M. A., Maag, D., Saini, A., Lorsch, J., & Hinnebusch, A. (2007) · EMBO Journal · doi:10.1038/sj.emboj.7601613 · Cited by 132
RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors
Santoro, M., Papotti, M. G., Chiappetta, G., Garcia-Rostan, G., Volante, M., Johnson, C., Camp, R. L., Pentimalli, F., Monaco, C., Herrero, A., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8174 · Cited by 117
Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis
Charles, R., Silva, J. M., Iezza, G., Phillips, W. A., & McMahon, M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0158-t · Cited by 109
Pita, J. M. G., Figueiredo, I., Moura, M. M., Leite, V. A. P. H., & Cavaco, B. M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1512 · Cited by 103
Ghossein, R. A., Katabi, N., & Fagin, J. A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1408 · Cited by 95
Self-citationArciuch, V. G. A., Russo, M. A., Dima, M., Kang, K. S., Dasrath, F., Liao, X.-H., Refetoff, S., Montagna, C., & Cristofano, A. D. (2011) · Oncotarget · doi:10.18632/oncotarget.380 · Cited by 85
Mutations of p53 in Thyroid Carcinoma with an Insular Component
Takeuchi, Y., Daa, T., Kashima, K., Yokoyama, S., Nakayama, I., & Noguchi, S. (1999) · Thyroid · doi:10.1089/thy.1999.9.377 · Cited by 68
Kurihara, T., Ikeda, S., Ishizaki, Y., Fujimori, M., Tokumoto, N., Hirata, Y., Ozaki, S., Okajima, M., Sugino, K., & Asahara, T. (2004) · Thyroid · doi:10.1089/thy.2004.14.1020 · Cited by 62
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Lee, J.-J., Au, A. Y. M., Foukakis, T., Barbaro, M., Kiss, N., Clifton-Bligh, R. J., Staaf, J., Borg, Å., Delbridge, L., Robinson, B. G., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0018 · Cited by 59
Poorly differentiated thyroid cancer
Patel, K. N., & Shaha, A. R. (2014) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000037 · Cited by 56
Champa, D., Russo, M. A., Liao, X. H., Refetoff, S., Ghossein, R. A., & Cristofano, A. D. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0268 · Cited by 34
Self-citationAnaplastic thyroid cancer: a comprehensive review of novel therapy
Kojic, S. L., Strugnell, S. S., & Wiseman, S. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.179 · Cited by 34
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Overview of the 2022 WHO Classification of Thyroid Neoplasms
Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., Sobrinho-Simões, M., Tallini, G., et al. (2022) · Endocrine Pathology · doi:10.1007/s12022-022-09707-3 · Cited by 1,158
Self-citationBiologic and Clinical Perspectives on Thyroid Cancer
Fagin, J. A., & Wells, S. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1501993 · Cited by 990
Self-citationSubbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Metadata
- Authors
- Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., Schultz, N., Berger, M. F., Sander, C., Taylor, B. S., Ghossein, R., Ganly, I., & Fagin, J. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2016-02-15
- Volume
- 126
- Issue
- 3
- Pages
- 1052-1066
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2279570938
- Cited by
- 1,284
- References
- 62
- FWCI
- 96.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.